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The well-established increased cardiovascular risk that is a
hallmark of chronic kidney disease (CKD) has directed
research to metabolic changes that are typical of CKD.
Epidemiological data point to derangements of mineral
metabolism to be involved in this risk profile. Subsequently,
newly discovered humoral factors—such as fibroblast growth
factor (FGF)-23—that are involved in mineral and vitamin D
homeostasis turned out to be associated with clinical
outcome, independently of the minerals they regulate.
Additional proteins involved in FGF-23 signaling, such as
Klotho, subsequently appeared to have FGF-23-independent
effects as well. In this review, the discovery, mode of action,
and clinical implications of these new factors are outlined.
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Identification of fibroblast growth factor (FGF)-23 has in
many ways revolutionized our current understanding of
mineral metabolism. It was initially discovered through
attempts to identify the predicted existence of ‘phosphato-
nins’, that is, phosphate-regulating hormones. Summarizing
the accomplishments made by many different researchers,
FGF-23 was found to be the primary cause of autosomal
dominant hypophosphatemic rickets,1 as well as an ectopi-
cally overproduced phosphaturic factor in patients with
tumor-induced osteomalacia.2
Structurally, FGF-23 was the twenty-third member of the
FGF family to be discovered with approximately 25–30%
homology to other FGFs. The first 24 amino acids of the amino
terminus function as a signal peptide for its transport from the
Golgi network to the extracellular space, and it is consequently a
circulating factor. The carboxy terminus is distinct from other
FGFs, providing unique characteristics in terms of glycosylation
and receptor activation. Two arginines—located at residues 176
and 179, respectively—provide a consensus site for proteolytic
cleavage by furin-like enzymes that inactivate and degrade the
active FGF-23 protein3,4 (Figure 1).
FGF-23 MECHANISMS AND REGULATION
There is striking concordance between the phenotypic
changes found in patients with primary or secondary FGF-
23 excess and/or deficiency and data from the extensive
animal and in vitro studies. Collectively, FGF-23 is a potent
negative regulator of circulating phosphate and 1,25-
dihydroxyvitamin D (calcitriol; 1,25D) levels.2,5 FGF-23
induces phosphaturia and lowers serum phosphate level
through reduction and internalization of the sodium–pho-
sphate cotransporters Npt2a and Npt2c in the kidney
proximal tubules.2,6,7 Further, FGF-23 directly suppresses
renal 1a-hydroxylase, leading to decreased conversion of
25-hydroxyvitamin D to its active metabolite 1,25D.2,8
Another role of FGF-23 in vitamin D metabolism is to
enhance the degradation pathway of vitamin D through
stimulation of the 24-hydroxylase. In the context of
physiology, more recent studies have also convincingly shown
that FGF-23, at least in the short term, directly decreases the
transcript level and secretion of parathyroid hormone
(PTH).9,10 The role of FGF-23 in regulation of PTH and
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secondary hyperparathyroidism in chronic kidney disease
(CKD) is currently under intense investigation (see below).
Whereas the main target of FGF-23 is the kidney, the
tissue source of FGF-23 is primarily bone, more specifically
osteocytes and osteoblasts.11,12 This further underscores the
fact that bone, beyond its capacity to store minerals and
provide mechanical support, is a highly active endocrine
organ. Further, there is robust evidence for the presence of a
previously unidentified bone–kidney axis. The interplay
between bone and kidney is not farfetched given
that the kidney is the main determinant of circulating
phosphate levels and actively participates in maintaining
calcium homeostasis, providing the skeleton with sufficient
minerals to form hydroxyapatite crystals at the mineraliza-
tion front.
Because FGF-23 holds promise as a biomarker for patient
outcome (see below), especially in patients with CKD, it is
important to understand its mode of regulation. The most
rapid stimuli for FGF-23 expression both in vitro and in vivo
is 1,25D, evoking a response in serum FGF-23 level within
3–4 h after intravenous administration.13 This completes a
feedback loop between vitamin D and FGF-23, and FGF-23
can in that sense be viewed as a counter-regulatory hormone
for vitamin D. As a result, the decline in vitamin D level that
occurs already in the initial phase of CKD can likely be
attributed to a rise in FGF-23 rather than a reduced renal
mass per se.
FGF-23 production is also promoted by high dietary
phosphate intake,14–18 as well as chronic hyperphosphatemia,
although rapid changes in serum phosphate concentrations
may not invoke acute increments in FGF-23. One hypothesis
is that FGF-23 responds to the net phosphate balance rather
than the serum phosphate level, but experimental data
supporting this hypothesis is weak. Further, the complete
chain of events from high dietary phosphate intake and
hyperphosphatemia to increased FGF-23 synthesis in bone is
currently unknown.
It also stands clear that vitamin D and phosphate regulate
FGF-23 through independent pathways, because mice lacking
the vitamin D receptor are still highly responsive to high
dietary phosphate intake.19 As a final remark, the response in
FGF-23 elicited by dietary phosphate intake in humans is
much weaker than that in rodents.
Despite the fact that FGF-23 belongs to the FGF family, in
which all members signal through one or several of the
known FGF receptors, it has been difficult to unveil the ‘true’
FGF-23 receptor both in vivo and in vitro. A major
breakthrough came from studies by Urakawa et al.,20 who
demonstrated that type I membrane-bound a-Klotho
(Klotho) directly binds to FGF receptor 1c, converting it
into a specific FGF-23 receptor (Figure 2).
Accordingly, FGF-23 is dependent on Klotho to induce
FGF-receptor signaling, at least in the kidneys and
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Figure 1 |The structure of fibroblast growth factor (FGF)-23. The diagram shows its FGF-like domain, the cleavage site, and the signal
peptide. Reprinted with permission from Yamashita3.
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Figure 2 |The fibroblast growth factor (FGF)-23 receptor. In
light blue, FGF receptor type-1 (FGFR-1). In dark blue, left-sided
membrane-bound Klotho; right-sided soluble, shed Klotho. The
red hexagon depicts FGF-23. FGF-23 signal transduction is
established when Klotho and FGFR-1 colocalize (left side). It is
unknown whether signal transduction can occur by soluble
Klotho (right side). In the kidney, signaling leads to down-
regulation of CYP27B1 and retrieval of phosphate transporters
in the proximal tubule (figure provided by J Hoenderop,
Department of Physiology, University Medical Center Nijmegen,
The Netherlands).
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parathyroid glands. The importance of Klotho in FGF-23
signaling is evidenced by Klotho-null mice, which harbor
nearly an identical biochemical phenotype compared with
FGF-23-knockout mice, despite exceptionally high circula-
tory FGF-23 levels.21,22 There are, however, still controversies
and unresolved issues around FGF-23 receptor signaling.
First, Klotho expression in the kidney is largely confined to
the distal tubules, whereas renal phosphate reabsorption
occurs in the proximal tubules. It is currently unclear how
FGF-23 signaling in distal tubules modifies phosphate
reabsorption in proximal tubules. Second, it is possible that
high levels of FGF-23, as present in many patients with
advanced CKD, could induce unspecific ‘off-target’ (that is,
Klotho-independent) FGF-receptor signaling.
FGF-23 and Klotho are likely to have important roles in
the pathophysiology of secondary hyperparathyroidism.
Although FGF-23 in the short term suppresses PTH
secretion, chronically high exposure of FGF-23 may override
this effect by lowering the systemic levels of 1,25D and
attenuate parathyroid vitamin D receptor signaling. Equally
important, it was recently demonstrated that FGF-23 reduces
the expression level of Klotho and that parathyroid Klotho
expression in surgically removed human parathyroid adeno-
mas declines in parallel with loss of renal function.23 This is a
plausible explanation for the parathyroid FGF-23 ‘resistance’
observed both in CKD patients and in rodent models of
experimentally induced renal failure.24,25
In summary, the discovery of FGF-23 and Klotho has led
to significant advances in our understanding of mineral
metabolism. This knowledge is now gradually being trans-
lated into the clinic with many potential implications,
including the endorsement of FGF-23 as a predictive
biomarker and the possibility of FGF-23/Klotho as a novel
therapeutic target.
KLOTHO
Klotho was discovered in 1997 in a mouse strain with a
phenotype consistent with premature aging as the principle
hallmark.21 Klotho has a short transmembrane domain and
two large extracellular domains,26 as shown in Figure 2.
Klotho exists as a membrane-bound form and two circulating
forms—one being the shed product of the membrane form
and the other a truncated form derived from the same gene
by alternative splicing.
Besides its above-described role as a cofactor in FGF-23
signaling, as shown in Figure 2, Klotho harbors at least two
important additional functions.27 First, it turns out that
Klotho has enzymatic activity, which resides on the
extracellular domain.28 The latter is of importance because
Klotho retains this enzymatic activity even when it is shed
from the plasma membrane. This is in contrast to the role of
Klotho as a cofactor in FGF-23, where the membrane-bound
form appears to be necessary.3 The best-described role of
this enzymatic activity of Klotho is its influence on the
transient receptor potential V5 at the luminal side of the
renal tubules.29 The glucuronidase-like activity of Klotho
modulates the sugar moieties, leading to sustained retention
of these highly important calcium transporters in the kidney.
In this way, Klotho promotes reabsorption of ultrafiltrated
calcium and prevents calciuria.29 This calcium-retaining
effect of Klotho in the healthy kidney is yet another
mechanism used to prevent overactivation of native vitamin
D, besides its suppressive role on vitamin D metabolism
mediated by FGF-23 signaling. Active vitamin D in turn
upregulates Klotho expression, closing a feedback loop
between vitamin D and Klotho.30 Very recently, it was shown
that Klotho, besides its involvement in calcium handling in
the kidney, also has direct effects on NaPt2a, the principle
phosphate transporter in the proximal tubule.31 Remarkable
about the latter finding is the fact that this effect is located on
the proximal tubule, although most investigators found the
distal tubule to be the most prominent site of Klotho
expression. The other remarkable fact is that the Klotho-
induced phosphaturic effects were also observed in FGF-23-
knockout mice, indicating a direct effect on NaPt2a.
A third recognized mode of action of Klotho is its
protective effect against oxidative stress. This was demon-
strated by Kuro-o et al.32,33 (who discovered Klotho in 1997).
They showed that the shed and circulating form of Klotho
activates FoxO, leading to enhanced expression of superoxide
dismutase.
Future research will likely unveil additional intriguing
effects of Klotho. Most recently, Klotho appeared to be
involved in endothelial integrity34 and endothelial-dependent
vasodilatation.35,36 Also, Klotho was shown to bind to type II
TGF-b receptor, thereby inhibiting TGF-b signaling and
suppression of renal interstitial fibrosis in an animal model.37
Finally, Klotho is expressed in the sinoatrial node and its
decreased expression leads to sinoatrial node malfunction
and premature death.38 All these findings are likely to be
most relevant to CKD patients, as both renal expression and
circulating levels of Klotho are reduced in this vulnerable
population.39
CLINICAL ASPECTS OF FGF-23
Given its central role in regulating mineral metabolism, the
obvious question arises: How important is FGF-23 clinically?
In early CKD, FGF-23 appears to be beneficial, compensating
for reduced phosphate excretory capacity by increasing
fractional excretion of phosphate. Although phosphate
retention is also a stimulus for PTH secretion, in early-stage
CKD the rise in FGF-23 is more pronounced than that of
PTH, possibly because of the inhibitory effects of FGF-23
on PTH.9,10 A trade-off of the increase of FGF-23 may be a
reduction in levels of 1,25D by the mechanism described
above. As CKD progresses, the efficacy of FGF-23 to induce
phosphaturia declines, due to at least two mechanisms. First,
the loss of functioning nephrons reduces the amount of
phosphate being ultrafiltrated; second, lowered renal Klotho
expression dismantles the FGF-23 receptor, leading to higher
phosphate reabsorption per nephron. For these reasons it
is expected that in advanced CKD, FGF-23 could be an
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indicator for dismal outcome. Indeed, this has been shown
for more advanced CKD, where FGF-23 independently
predicted progression of disease.40,41 In the study by
Fliser et al., the predictive value of FGF-23 for disease
progression was surpassed only by proteinuria.40 Despite
their independency in predicting disease progression, FGF-23
levels and proteinuria are positively associated across several
ranges of CKD, as recently demonstrated by Vervloet et al.42
The most convincing argument for the clinical meaning of
FGF-23 comes from the analysis of a large cohort of dialysis
patients, in which an independent association between FGF-
23 and mortality was demonstrated, as shown in Figure 3.43
Even after correcting for established predictors of mortality,
the hazard ratios for the higher ranges of FGF-23 outranked
the others.
The fact that correcting for phosphate level, PTH, and
vitamin D use did not mitigate predictive value of FGF-23 for
dismal outcome is remarkable, because these parameters were
thought to be in the same causal pathway as FGF-23. This
could mean that FGF-23 is a sensitive marker for phosphate
burden, or induces harm itself. In support for the first
hypothesis, FGF-23 has, in large observational studies of
elderly subjects with normal or only mildly impaired renal
function, been associated with vascular dysfunction,44 total
atherosclerotic burden,45 and left ventricular hypertrophy.46
Further, FGF-23 is also a predictor of fracture risk in this
population, another central feature of CKD–mineral and
bone disorder (CKD–MBD).47 Arguments for the latter come
from a recent study indicating that FGF-23 influences flow-
mediated vasodilation in CKD stage 3 and 4 patients.48
Additional arguments, albeit indirect, come from recent
research indicating FGF-23 as a factor associated with left
ventricular mass index independent from brain natriuretic
peptide,49 myocardial performance,50 and coronary artery
disease.51
If FGF-23 indeed turns out to be either a sensitive
biomarker of phosphate load, or has some different
pathological effect in advanced stages of CKD, the next
clinical question would be: Is it modifiable? From a
theoretical point of view, options to lower FGF-23 would
be to reduce levels of active vitamin D, PTH, and phosphate
burden. Indeed, parathyroidectomy has been shown to
induce a significant decline in FGF-23,52 possibly because
of the direct effect of PTH on FGF-23 production.53
Lowering dietary phosphate intake decreases FGF-23 in
healthy volunteers with a lag time,14 but this approach is not
likely to be sufficient in CKD. The use of phosphate binders
has shown inconsistent results as FGF-23-lowering agents.
Sevelamer declined FGF-23 in a dose-dependent manner in
an experimental model of uremia,54 and this was confirmed
clinically after 6 weeks of treatment.55 Use of calcium-based
binder therapy did not change FGF-23 significantly in that
study. These findings were confirmed in a cohort of 72
hemodialysis patients followed up for 1 year.56 Use of
lanthanum carbonate, however, while significantly reducing
24-h urine phosphate excretion, indicating adequate phos-
phate binding, did not change FGF-23.17 This absence of
effect of lanthanum carbonate on FGF-23 in this study,
however, could have been caused by a too short study period
of two weeks only, since more time may be required for FGF-
23 to slow down. Indeed, in a very recent study, extended use
of lanthanum carbonate in an otherwise comparable study
population did significantly suppress FGF-23 by almost
25%.57 Lowering levels of 1,25D in CKD as a way to decline
FGF-23 is not an attractive option for obvious reasons.58
Currently, there is no evidence supporting the fact that
FGF-23 is a modifiable risk factor that leads to improvement
of clinical outcomes such as mortality. Prospective trials are
underway that study changes in vascular function after FGF-
23-targeted interventions. A critical question is whether FGF-
23 is purely a biomarker of phosphate exposure or if it has
‘off-target’ effects directly contributing to vascular toxicity. If
FGF-23 levels are reduced by means of improving phosphate
control, it will be difficult to analyze whether changes in
outcomes are related to a more stringent phosphate control
or a consequence of a lower FGF-23 level per se. Another
option that could shed light on this question would be to
intervene at the level of FGF-23-producing cells, either
osteocytes in bone or ectopic production from bone cells in
the vessel wall in the presence of calcified arterial lesions,59 by
using FGF-23 blocking agents or upstream transcriptional
inhibitors of FGF-23.
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Figure 3 |Odds ratios for death in hemodialysis patients in
relation to quartiles of fibroblast growth factor (FGF)-23
levels. Both unadjusted and fully adjusted models demonstrate a
strong and graded association. *Po0.05. Reprinted with
permission from Gutierrez et al.43 R, reference.
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From the convincing epidemiological association between
FGF-23 and mortality in dialysis patients,43 an enigma
emerges: How is it possible that a hormone such as FGF-23
has such an impact on outcome, while its main target
organ—the kidney—is non-functioning? Of course, the
parathyroid is another target for FGF-23; however, in CKD,
PTH suppression by FGF-23 is abolished by parathyroid
resistance.23,25 Although it is likely that all FGF-23 actions
require the presence of the FGF receptor 1c and membrane
Klotho,60 theoretically, other tissues expressing Klotho and
FGF receptor 1c might be unidentified targets for FGF-23.
Recently, both Klotho and FGF receptor-1 were shown to be
present in human aortic smooth muscle cell,61 but at present
it is unclear whether this is membrane-bound or soluble
Klotho, and whether actual signal transduction by FGF-23
can occur at this site. Nevertheless, the arterial wall and
cardiomyocytes as target tissues for FGF-23 action is an
attractive concept, given the central role of cardiovascular
disease in CKD-associated morbidity. Alternatively, indirect
effects of FGF-23 on the arterial wall are also plausible. These
could be mediated by phosphate itself or by a reduction in
Klotho level, given that FGF-23 suppresses Klotho,23 and
recent data suggest that it is implicated in the process of
arterial calcification.62
In conclusion, data pointing to FGF-23 and Klotho being
active factors in the burden of CKD are ever increasing. Both
epidemiological data and pathophysiological mechanisms
have set the stage for targeted intervention in the clinical
setting. These new apparently important factors in CKD
provide hope for improved future targeted therapy in CKD.
DISCLOSURE
This issue was organized by the VDR Expert Centers and was funded
by Abbott Laboratories with a collaborative effort to advance and
support the science and the improvement of quality of life for renal
patients. MGV has received consulting fees from or participated in
paid advisory boards for Amgen, Abbott Laboratories, and Fresenius;
received lecture fees for speaking at the invitation of Abbott
Laboratories and Amgen; and received grant support from Genzyme
and Shire. TEL has received consulting fees from or participated in
paid advisory boards for Genzyme, Abbott Laboratories, and
Swedish-Orphan, and has received lecture fees for speaking at the
invitation of Amgen, AstraZeneca, Shire, Genzyme, and Abbott
Laboratories.
REFERENCES
1. ADHR Consortium. Autosomal dominant hypophosphataemic rickets
is associated with mutations in FGF-23. Nat Genet 2000; 26:
345–348.
2. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of
FGF-23 as a causative factor of tumor-induced osteomalacia. Proc Natl
Acad Sci U S A 2001; 98: 6500–6505.
3. Yamashita T. Structural and biochemical properties of fibroblast growth
factor 23. Ther Apher Dial 2005; 9: 313–318.
4. White KE, Carn G, Lorenz-Depiereux B et al. Autosomal-dominant
hypophosphatemic rickets (ADHR) mutations stabilize FGF-23.
Kidney Int 2001; 60: 2079–2086.
5. Shimada T, Kakitani M, Yamazaki Y et al. Targeted ablation of FGF-23
demonstrates an essential physiological role of FGF-23 in phosphate and
vitamin D metabolism. J Clin Invest 2004; 113: 561–568.
6. Bai X, Miao D, Li J et al. Transgenic mice overexpressing human fibroblast
growth factor 23 (R176Q) delineate a putative role for parathyroid
hormone in renal phosphate wasting disorders. Endocrinology 2004; 145:
5269–5279.
7. Larsson T, Marsell R, Schipani E et al. Transgenic mice expressing
fibroblast growth factor 23 under the control of the alpha1(I) collagen
promoter exhibit growth retardation, osteomalacia, and disturbed
phosphate homeostasis. Endocrinology 2004; 145: 3087–3094.
8. Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator
of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res
2004; 19: 429–435.
9. Krajisnik T, Bjo¨rklund P, Marsell R et al. Fibroblast growth factor-23
regulates parathyroid hormone and 1alpha-hydroxylase expression in
cultured bovine parathyroid cells. J Endocrinol 2007; 195: 125–131.
10. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target
organ for FGF-23 in rats. J Clin Invest 2007; 117: 4003–4008.
11. Liu S, Guo R, Simpson LG et al. Regulation of fibroblastic growth factor
23 expression but not degradation by PHEX. J Biol Chem 2003; 278:
37419–37426.
12. Riminucci M, Collins MT, Fedarko NS et al. FGF-23 in fibrous dysplasia of
bone and its relationship to renal phosphate wasting. J Clin Invest 2003;
112: 683–692.
13. Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counter-
regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006;
17: 1305–1315.
14. Vervloet MG, van Ittersum FJ, Bu¨ttler RM et al. Effects of dietary
phosphate and calcium intake on fibroblast growth factor-23.
Clin J Am Soc Nephrol 2010; 6: 83–89.
15. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship
to dietary phosphate and renal phosphate handling in healthy young
men. J Clin Endocrinol Metab 2005; 90: 1519–1524.
16. Nishida Y, Taketani Y, Yamanuka-Okumura H et al. Acute effect of oral
phosphate loading on serum fibroblast growth factor 23 levels in healthy
men. Kidney Int 2006; 70: 2141–2147.
17. Isakova T, Gutierrez OM, Smith K et al. Pilot study of dietary phosphorus
restriction and phosphorus binders to target fibroblast growth factor 23
in patients with chronic kidney disease. Nephrol Dial Transplant 2010; 26:
584–591.
18. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates
serum fibroblast growth factor-23 concentrations in healthy men.
J Clin Endocrinol Metab 2006; 91: 3144–3149.
19. Yu X, Sabbagh Y, Davis SI et al. Genetic dissection of phosphate- and
vitamin D-mediated regulation of circulating FGF-23 concentrations.
Bone 2005; 36: 971–977.
20. Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical
FGF receptor into a specific receptor for FGF-23. Nature 2006; 444:
770–774.
21. Kuro-o M, Matsumura Y, Yamazaki Y et al. Mutation of the mouse
klotho gene leads to a syndrome resembling ageing. Nature 1997; 390:
45–51.
22. Shimada T, Urakawa I, Yamazaki Y et al. FGF-23 transgenic mice
demonstrate hypophosphatemic rickets with reduced expression of
sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun
2004; 314: 409–414.
23. Krajisnik T, Olauson H, Mirza MA et al. Parathyroid Klotho and FGF-
receptor 1 expression decline with renal function in hyperparathyroid
patients with chronic kidney disease and kidney transplant recipients.
Kidney Int 2010; 78: 1024–1032.
24. Galitzer H, Ben-Dov IZ, Silver J et al. Parathyroid cell resistance to
fibroblast growth factor 23 in secondary hyperparathyroidism of chronic
kidney disease. Kidney Int 2010; 77: 211–218.
25. Canalejo R, Canalejo A, Martinez-Moreno JM et al. FGF23 fails to inhibit
uremic parathyroid glands. J Am Soc Nephrol 2010; 21: 1125–1135.
26. Shiraki-Iida T, Aizawa H, Matsumura Y et al. Structure of the mouse klotho
gene and its two transcripts encoding membrane and secreted protein.
FEBS Lett 1998; 424: 6–10.
27. Torres PU, Irie´ D, Molina-Ble´try V et al. Klotho: an antiaging protein
involved in mineral and vitamin D metabolism. Kidney Int 2007; 71:
730–737.
28. Tohyama O, Imura A, Iwano A et al. Klotho is a novel beta-glucuronidase
capable of hydrolyzing steroid beta-glucuronides. J Biol Chem 2004; 279:
9777–9784.
29. Chang Q, Hoefs S, van der Kemp AW et al. The beta-glucuronidase klotho
hydrolyzes and activates the TRPV5 channel. Science 2005; 310: 490–493.
30. Tsujikawa H, Kurotaki Y, Fujimori T et al. Klotho, a gene related to a
syndrome resembling human premature aging, functions in a negative
regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003; 17:
2393–2403.
134 Kidney International Supplements (2011) 1, 130–135
rev iew MG Vervloet and TE Larsson: FGF-23 in CKD
31. Hu MC, Shi M, Zhang J et al. Klotho: a novel phosphaturic substance
acting as an autocrine enzyme in the renal proximal tubule. FASEB J 2010;
24: 3438–3450.
32. Kuro-o M. Klotho as a regulator of oxidative stress and senescence.
Biol Chem 2008; 389: 233–241.
33. Yamamoto M, Clark JD, Pastor JV et al. Regulation of oxidative
stress by the anti-aging hormone klotho. J Biol Chem 2005; 280:
38029–38034.
34. Kusaba T, Okigawa M, Matui A et al. Klotho is associated with VEGF
receptor-2 and the transient receptor potential canonical-1 Ca2+ channel
to maintain endothelial integrity. Proc Natl Acad Sci U S A 2010; 107:
19308–19313.
35. Nagai R, Saito Y, Ohyama Y et al. Endothelial dysfunction in the klotho
mouse and downregulation of klotho gene expression in various animal
models of vascular and metabolic diseases. Cell Mol Life Sci 2000; 57:
738–746.
36. Nakamura T, Saito Y, Ohyama Y et al. Production of nitric oxide, but
not prostacyclin, is reduced in klotho mice. Jpn J Pharmacol 2002; 89:
149–156.
37. Doi S, Zou Y, Togao O et al. Klotho inhibits transforming growth
factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and
cancer metastasis in mice. J Biol Chem 2011; 286: 8655–8665.
38. Takeshita K, Fujimori T, Kurotaki Y et al. Sinoatrial node dysfunction and
early unexpected death of mice with a defect of klotho gene expression.
Circulation 2004; 109: 1776–1782.
39. Kuro-o M. Phosphate and Klotho. Kidney Int Suppl 2011; 121:
S20–S23.
40. Fliser D, Kollerits B, Never U et al. Fibroblast growth factor 23 (FGF-23)
predicts progression of chronic kidney disease: the Mild to Moderate
Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600–2608.
41. Titan SM, Zatz R, Graciolli FG et al. FGF-23 as a predictor of renal outcome
in diabetic nephropathy. Clin J Am Soc Nephrol 2010; 6: 241–247.
42. Vervloet M, van Zuilen AD, Blankenstijn PJ et al. Fibroblast growth factor
23 is associated with proteinuria. J Am Soc Nephrol 2010; 21: 186A.
43. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor
23 and mortality among patients undergoing hemodialysis. N Engl J Med
2008; 359: 584–592.
44. Mirza MA, Larsson A, Lind L et al. Circulating fibroblast growth factor-23 is
associated with vascular dysfunction in the community. Atherosclerosis
2009; 205: 385–390.
45. Mirza MA, Hansen T, Johansson L et al. Relationship between circulating
FGF-23 and total body atherosclerosis in the community. Nephrol Dial
Transplant 2009; 24: 3125–3131.
46. Mirza MA, Larsson A, Melhus H et al. Serum intact FGF-23 associate with
left ventricular mass, hypertrophy and geometry in an elderly population.
Atherosclerosis 2009; 207: 546–551.
47. Mirza MA, Karlsson MK, Mellstro¨m D et al. Serum fibroblast growth
factor-23 (FGF-23) and fracture risk in elderly men. J Bone Miner Res 2011;
26: 857–864.
48. Yilmaz MI, Sonmez A, Saglam M et al. FGF-23 and vascular dysfunction
in patients with stage 3 and 4 chronic kidney disease. Kidney Int 2010; 78:
679–685.
49. Negishi K, Kobayashi M, Ochiai I et al. Association between fibroblast
growth factor 23 and left ventricular hypertrophy in maintenance
hemodialysis patients. Comparison with B-type natriuretic peptide and
cardiac troponin T. Circ J 2010; 74: 2734–2740.
50. Kirkpantur A, Balci M, Gurbuz CA et al. Serum fibroblast growth factor-23
(FGF-23) levels are independently associated with left ventricular mass
and myocardial performance index in maintenance haemodialysis
patients. Nephrol Dial Transplant 2011; 26: 1346–1354.
51. Kanbay M, Nicoleta M, Selcoki Y et al. Fibroblast growth factor 23 and
fetuin A are independent predictors for the coronary artery disease
extent in mild chronic kidney disease. Clin J Am Soc Nephrol 2010; 5:
1780–1786.
52. Sato T, Tominaga Y, Ueki T et al. Total parathyroidectomy reduces
elevated circulating fibroblast growth factor 23 in advanced secondary
hyperparathyroidism. Am J Kidney Dis 2004; 44: 481–487.
53. Lavi-Moshayoff V, Wasserman G, Meir T et al. PTH increases FGF-23 gene
expression and mediates the high-FGF-23 levels of experimental kidney
failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol
2010; 299: F882–F889.
54. Nagano N, Miyata S, Abe M et al. Effect of manipulating serum
phosphorus with phosphate binder on circulating PTH and FGF-23 in
renal failure rats. Kidney Int 2006; 69: 531–537.
55. Oliveira RB, Cancela AL, Graciolli FG et al. Early control of PTH and FGF-23
in normophosphatemic CKD patients: a new target in CKD–MBD therapy?
Clin J Am Soc Nephrol 2010; 5: 286–291.
56. Cancela AL, Oliveira RB, Graciolli FG et al. Fibroblast growth factor 23 in
hemodialysis patients: effects of phosphate binder, calcitriol and calcium
concentration in the dialysate. Nephron Clin Pract 2011; 117: c74–c82.
57. Gonzalez-Parra E, Gonzalez-Casaus ML, Gala´n A et al. Lanthanum
carbonate reduces FGF23 in chronic kidney disease stage 3 patients.
Nephrol Dial Transplant 2011; 26: 2567–2571.
58. Vervloet MG, Twisk JW. Mortality reduction by vitamin D receptor
activation in end-stage renal disease: a commentary on the robustness
of current data. Nephrol Dial Transplant 2009; 24: 703–706.
59. Voigt M, Fischer DC, Rimpau M et al. Fibroblast growth factor (FGF)-23
and fetuin-A in calcified carotid atheroma. Histopathology 2010; 56:
775–788.
60. Farrow EG, Davis SI, Summers LJ et al. Initial FGF-23-mediated signaling
occurs in the distal convoluted tubule. J Am Soc Nephrol 2009; 20:
955–960.
61. Lim K, Lu TS, Zehnder D et al. Development of Klotho-FGFR1/3
dependent resistance to FGF-23 in human aortic smooth muscle cells
exposed to calcifying stress. J Am Soc Nephrol 2010; 21: 140A.
62. Hu MC, Shi M, Zhang J et al. Klotho deficiency causes vascular
calcification in chronic kidney disease. J Am Soc Nephrol 2011; 22:
124–136.
Kidney International Supplements (2011) 1, 130–135 135
MG Vervloet and TE Larsson: FGF-23 in CKD rev iew
